Gilead Sciences aims to license its new hepatitis C drug Sovaldi to three or four Indian generic manufacturers to allow sales of the medicine at lower prices in some 60 developing nations.
Clifford Samuel, head of access operations and emerging markets at the US drugmaker, told Reuters he expected to have deals in place shortly with the Indian firms, which would be able to produce the drug in high volumes and at low margins.
Gilead is under pressure to address the high cost of its breakthrough pill, which is the first of a new wave of drugs that have been shown to raise cure rates and cut treatment duration without the side effects.
“We’re in the midst of discussions right now. We’re nailing down the geographical scope, and we should have these licenses in place and ready to go in short order,” Samuel said in London.
He said Gilead was looking to strike deals with firms that had proven experience in producing generic versions of its HIV/AIDS drugs and that the company is currently discussing a price of $2,000.